Antimicrobial peptide hLF1-11 directs granulocyte-macrophage colony-stimulating factor-driven monocyte differentiation toward macrophages with enhanced recognition and clearance of pathogens.

Antimicrobial Agents and Chemotherapy
Anne M van der DoesPeter H Nibbering

Abstract

The human lactoferrin-derived peptide hLF1-11 displays antimicrobial activities in vitro and is effective against infections with antibiotic-resistant bacteria and fluconazole-resistant Candida albicans in animals. However, the mechanisms underlying these activities remain largely unclear. Since hLF1-11 is ineffective in vitro at physiological salt concentrations, we suggested modulation of the immune system as an additional mechanism of action of the peptide. We investigated whether hLF1-11 affects human monocyte-macrophage differentiation and determined the antimicrobial activities of the resulting macrophages. Monocytes were cultured for 7 days with GM-CSF in the presence of hLF1-11, control peptide, or saline for various intervals. At day 6, the cells were stimulated with lipopolysaccharide (LPS), lipoteichoic acid (LTA), or heat-killed C. albicans for 24 h. Thereafter, the levels of cytokines in the culture supernatants, the expression of pathogen recognition receptors, and the antimicrobial activities of these macrophages were determined. The results showed that a short exposure of monocytes to hLF1-11 during GM-CSF-driven differentiation is sufficient to direct differentiation of monocytes toward a macrophage subset char...Continue Reading

References

Nov 18, 2000·Antimicrobial Agents and Chemotherapy·A LupettiP H Nibbering
Jan 25, 2002·Nature·Michael Zasloff
Dec 25, 2002·Antimicrobial Agents and Chemotherapy·Antonella LupettiPeter H Nibbering
Dec 13, 2005·Current Opinion in Immunology·David A Hume
Jun 8, 2006·Biochimica Et Biophysica Acta·David I ChanHans J Vogel
Dec 13, 2006·Nature Biotechnology·Robert E W Hancock, Hans-Georg Sahl
Jan 12, 2007·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Mohamed Zaiou
Mar 27, 2007·Nature Biotechnology·Monisha G ScottRobert E W Hancock
Oct 9, 2007·The Journal of Infectious Diseases·Antonella LupettiPeter H Nibbering
Nov 21, 2007·Microbes and Infection·D M E BowdishS Gordon
Dec 28, 2007·Trends in Microbiology·Janet A Willment, Gordon D Brown
Apr 22, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kevin N CouperEleanor M Riley
Jun 14, 2008·Nature Reviews. Immunology·John A Hamilton
Sep 9, 2009·BMC Medicine·Walter J F M van der VeldenJ Peter Donnelly

❮ Previous
Next ❯

Citations

Jun 21, 2008·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A LupettiP H Nibbering
Aug 17, 2011·Antimicrobial Agents and Chemotherapy·Bruk MensaWilliam F DeGrado
Dec 18, 2013·PLoS Pathogens·Praveen PapareddyArtur Schmidtchen
Mar 20, 2010·Biometals : an International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine·Anne M van der DoesPeter H Nibbering
May 17, 2011·Cellular and Molecular Life Sciences : CMLS·Amy T Y YeungRobert E W Hancock
Apr 4, 2015·Expert Review of Anti-infective Therapy·Laszlo Otvos, Eszter Ostorhazi
Nov 13, 2013·Expert Opinion on Investigational Drugs·Ze-Qi XuJohn Flavin
Jul 11, 2012·Current Opinion in Pharmacology·Michael John Dawson, Richard W Scott
Dec 15, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·A de BreijT F Moriarty
Oct 16, 2010·Annals of the New York Academy of Sciences·Erin F NichollsRobert E W Hancock
Dec 3, 2014·Peptides·Isabel C M FensterseiferOctavio L Franco
Sep 6, 2014·Medical Microbiology and Immunology·Olachi AnuforomLaura V Piddock
May 8, 2016·Peptides·Camilla BjörnJoakim Håkansson
May 7, 2013·Developmental and Comparative Immunology·Tryntsje CuperusHenk P Haagsman
Aug 1, 2016·Journal of Nephrology·Jun-Jun Luan, Guang-Qun Xing
Feb 3, 2018·Clinical and Experimental Immunology·L WisgrillK Sadeghi
Feb 20, 2014·Journal of Leukocyte Biology·Min WanJesper Z Haeggström
Dec 17, 2011·Nature Reviews. Drug Discovery·Christopher D FjellGisbert Schneider
Feb 13, 2018·Experimental and Therapeutic Medicine·Lijun HuoJia Liu
Mar 27, 2020·Current Topics in Medicinal Chemistry·Bruna de Oliveira Costa, Octávio Luiz Franco
Jan 14, 2017·Frontiers in Cellular and Infection Microbiology·Margit MahlapuuCamilla Björn
Apr 24, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anne M van der DoesPeter H Nibbering
Dec 3, 2020·Journal of Microbiology and Biotechnology·Manigandan KrishnanYangmee Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.